Baxdrostat lowers stubborn high blood pressure

A new drug, baxdrostat, significantly lowers blood pressure in patients with difficult-to-control hypertension, offering hope to millions worldwide. The Phase III BaxHTN trial showed baxdrostat reduced blood pressure by 9-10 mmHg more than placebo, with about 40% of patients reaching healthy levels. This treatment targets aldosterone, a hormone linked to high blood pressure, potentially benefiting up to half a billion people globally.